Symplmed Pharmaceuticals LLC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

XOMA 985 · Immunology
XOMA 985 is a monoclonal antibody that targets and inhibits IL-15, a key cytokine involved in immune cell activation and proliferation.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Symplmed Pharmaceuticals LLC portfolio CI brief
Symplmed Pharmaceuticals LLC pipeline updates RSS

Frequently asked questions about Symplmed Pharmaceuticals LLC

What is Symplmed Pharmaceuticals LLC's pipeline?

Symplmed Pharmaceuticals LLC has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include XOMA 985.

Sector hub: All tracked pharma companies